# Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery

> **NCT01623531** · PHASE3 · COMPLETED · sponsor: **Nova Scotia Health Authority** · enrollment: 62 (actual)

## Conditions studied

- Cardiac Complication During Procedure

## Interventions

- **DRUG:** Fibrinogen

## Key facts

- **NCT ID:** NCT01623531
- **Lead sponsor:** Nova Scotia Health Authority
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2019-03-31
- **Final completion:** 2019-06-30
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2020-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01623531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01623531, "Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01623531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*